Companion Diagnostics (Cdx) Development Market Growth and Development: Regional Demand, Segment by Types and End-User By 2035

Companion diagnostics (CDx) enable the identification of patients most likely to benefit from specific therapies, particularly in oncology. Development services span feasibility studies, assay development, analytical and clinical validation, and manufacturing, using techniques such as NGS, PCR, IHC, and flow cytometry.

Supporting this specialized workflow is the Companion Diagnostics (CDx) Development Market, valued at approximately USD 779–892 million in 2025–2026 and projected to reach USD 1,796 million by 2035 at a CAGR of about 9.7%. Oncological disorders currently dominate demand.

More than 155 service providers are active globally. Key players include Almac Diagnostics, Labcorp, QIAGEN, Quest Diagnostics, Eurofins, and others. As precision medicine expands beyond oncology and more targeted therapies require co-developed diagnostics, the CDx development services market is expected to grow steadily through 2035.
Read More: https://www.rootsanalysis.com/reports/companion-diagnostics-services/297.html